Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT2 | O60551 | 5/20 | 0.40 |
| ▸ | NMT1 | P30419 | 5/20 | 0.40 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 4/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776913 | 0.90 | NMT2 (0.39) | NMT2NMT1FAPCTSLFURIN | |
| SCHEMBL20349812 | 0.90 | NMT2 (0.39) | NMT2NMT1FAPCTSLFURIN | |
| SCHEMBL17860180 | 0.90 | HRH1 (0.38) | NMT2NMT1CTSLFURINPRSS1 | |
| SCHEMBL20287670 | 0.88 | NMT1 (0.41) | NMT2NMT1FAPCTSLFURIN | |
| SCHEMBL17860132 | 0.88 | NMT1 (0.41) | NMT2NMT1FAPCTSLFURIN | |
| SCHEMBL22134346 | 0.88 | NMT1 (0.41) | NMT2NMT1FAPCTSLFURIN | |
| SCHEMBL24993722 | 0.86 | FURIN (0.42) | NMT2NMT1CTSLFURINPRSS1 | |
| SCHEMBL29647873 | 0.86 | FAP (0.38) | NMT2NMT1FAPFURINPRSS1 | |
| SCHEMBL18909077 | 0.83 | NMT1 (0.48) | NMT2NMT1TLR2ROCK2PRKACA | |
| SCHEMBL19619238 | 0.83 | FAP (0.40) | NMT2NMT1FAPCTSLFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744205-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies | KIF23, KIF2C, KIF18A | NMT2 3978/4885NMT1 3985/4885FAP 3328/4885 |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | NMT2 3995/4885NMT1 3996/4885FAP 4588/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | NMT2 3995/4885NMT1 3996/4885FAP 4588/4885 |
| US-20160346402-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) | KIF5B, KIF23, KIF2C | NMT2 3591/4885NMT1 3751/4885FAP 4134/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | NMT2 2936/4885NMT1 2582/4885FAP 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.